Side-by-side · Research reference

AHK-CuvsLL-37

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-MechanisticHUMAN-REVIEWED14/43 cited

BHuman-MechanisticHUMAN-REVIEWED15/35 cited

AHK-Cu

Tripeptide-Copper Complex · Cosmetic

10⁻¹² – 10⁻⁹ MActive range (in vitro)Pyo 2007

Dermal papilla cellsPrimary targetPyo 2007

TopicalRoute

Topical · Scalp / Skin

LL-37

Cathelicidin · Human AMP

Broad-spectrumAntimicrobial activity

Membrane disruptionPrimary mechanismLu 2026 He 2026

Innate immunityHost defense rolePinheiro 2026 Zhang 2026

Endogenous · Secreted at inflammation sites

01Mechanism of Action

Parameter

AHK-Cu

LL-37

Primary target

Dermal papilla cells (DPCs) — specialized fibroblasts in hair follicle morphogenesisPyo 2007

Bacterial membranes · Phosphatidylserine-exposed cellsHe 2026 Lu 2026

Pathway

AHK-Cu → DPC proliferation → VEGF elevation, TGF-β1 suppression → Angiogenesis, follicle elongationPyo 2007

hCAP-18 precursor → Proteinase-3 cleavage → LL-37 release → Membrane insertion/disruption

Downstream effect

Stimulates hair follicle elongation ex vivo, reduces dermal papilla cell apoptosis, elevates Bcl-2/Bax ratio, reduces cleaved caspase-3 and PARPPyo 2007

Membrane permeabilization, cytokine induction, autophagy, phagosome-lysosome fusion, chemotaxisAhmad 2026 Zhang 2026

Feedback intact?

—

Origin

Synthetic tripeptide with Cu²⁺ chelation — alanine substitution variant of GHK-Cu

Endogenous human cathelicidin (37-AA fragment, residues 134–170 of hCAP-18)

Antibody development

—

02Dosage Protocols

Parameter

AHK-Cu

LL-37

Effective concentration (in vitro)

10⁻¹² – 10⁻⁹ MPyo 2007

Stimulated human hair follicle elongation ex vivo and DPC proliferation in vitro.

—

Topical formulation

0.001–0.01% (estimated cosmetic range)

No standardized human protocol published — extrapolated from in vitro data.

—

Frequency

Once or twice daily (topical application)

—

Route

Topical — scalp or dermal application

—

Evidence basis

Ex vivo hair follicle / in vitro DPC studiesPyo 2007

In vitro, animal models, human observational

Duration

Not established — cosmetic protocols typically 8–12 weeks

—

Endogenous expression

—

Constitutive in neutrophils, epithelial tissues

Upregulated during infection and inflammation.Pinheiro 2026

Exogenous (experimental)

—

Dose varies by study; antimalarial ~10–50 μM in vitro

No FDA-approved exogenous formulation.

Plasma levels (malaria)

—

Elevated in infected patients and miceHe 2026

Exogenous administration reduced parasitemia in murine models.He 2026

04Side Effects & Safety

Parameter

AHK-Cu

LL-37

Local irritation

Mild erythema, pruritus at application site (copper peptide class effect)

—

Copper sensitivity

Rare hypersensitivity reaction in copper-sensitive individuals

—

Systemic absorption

Minimal via topical route — systemic copper toxicity unlikely at cosmetic doses

—

Data limitations

No published human safety trials — cosmetic use presumed safe per class precedent (GHK-Cu)

—

Cytotoxicity (high dose)

—

Membrane disruption in host cells at supraphysiological concentrations

Pro-inflammatory signaling

—

Can exacerbate inflammation in certain contexts (context-dependent)Pinheiro 2026

Biofilm formation risk

—

LL-37-DNA complexes may stabilize dental plaque biofilmsTanabe 2026

Theoretical cancer risk

—

Immunomodulatory roles in tumor microenvironment under investigation

Absolute Contraindications

AHK-Cu

·Known copper allergy or Wilson's disease

LL-37

—

Relative Contraindications

AHK-Cu

·Broken or inflamed skin (increased absorption risk)
·Concurrent use of other copper-containing formulations

LL-37

·Active autoimmune disease (theoretical immune dysregulation)

05Administration Protocol

Parameter

AHK-Cu

LL-37

1. Topical application

Apply to clean, dry scalp or target dermal area. Typical cosmetic formulations: 0.001–0.01% AHK-Cu in serum or cream base.

LL-37 is constitutively expressed in neutrophils and epithelial cells, cleaved from hCAP-18 by proteinase-3 at sites of infection or inflammation.

2. Frequency

Once or twice daily. Evening application preferred for overnight contact time.

Synthetic LL-37 and derivatives (e.g., SAMP-12aa) tested in vitro and animal models. Administered via topical, intraperitoneal, or intravenous routes in research settings.

3. Scalp preparation

For hair growth: apply directly to scalp, massage gently. No need to rinse. Allow absorption for minimum 2–4 hours.

LL-37 is resistant to pepsin degradation at gastric pH. Synthetic short peptides designed to retain this stability while reducing toxicity.Lu 2026

4. Storage

Room temperature, protected from light. Copper complexes may degrade in UV exposure.

—

5. Duration

Minimum 8–12 weeks to assess efficacy in hair growth applications, per typical cosmetic peptide protocols.

—

06Stack Synergy

AHK-Cu

+ GHK-Cu

Moderate

View GHK-Cu →

Both tripeptide-copper complexes share overlapping angiogenic and wound-healing mechanisms (VEGF elevation, TGF-β modulation, fibroblast proliferation). AHK-Cu's alanine substitution may offer distinct receptor affinity or pharmacokinetics. Co-formulation could provide complementary dermal signaling, though no direct synergy studies exist. Often used interchangeably or in alternating protocols.

AHK-Cu: 0.001–0.01% topical · AM
GHK-Cu: 0.001–0.01% topical · PM
Frequency: Daily alternation or combined formulation
Primary benefit: Comprehensive dermal regeneration, angiogenesis, hair follicle support

LL-37

— no documented stacks